Definitive weekly hypofractionated radiotherapy in cutaneous squamous cell carcinoma: response rates and outcomes in elderly patients unfit for surgery.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
27
10
2021
received:
28
07
2021
accepted:
11
11
2021
pubmed:
25
11
2021
medline:
23
7
2022
entrez:
24
11
2021
Statut:
ppublish
Résumé
The optimal definitive radiotherapy (RT) scheme in cutaneous squamous cell carcinoma (cSCC) remains controversial, especially in elderly patients. Data of elderly patients with cSCC lesion(s) treated with weekly hypofractionated RT (8 Gy per week per 7-8 weeks) were analyzed. Eighteen patients (median age 89 years) with 23 cSCC lesions have been identified including nine males (50%) and nine females (50%). The most common tumor localization was the head and neck region (n = 21; 91.3%), and the majority of lesions (n = 15; 65.2%) was stage ≥ III. At diagnosis, pain and bleeding were ascribed in 13 (56.5%) and eight (34.8%) cSCC, respectively. Compliance with weekly hypofractionated RT was excellent. The overall response rate at 12 weeks after treatment was 95.7%. Bleeding and pain relief were achieved in all cases. Severe toxicity was not recorded. The 1-year overall survival was 66.0%. The 1-year progression-free survival was 58.7%. Weekly hypofractionated RT provides a safe, efficient, and cost-effective treatment in elderly cSCC patients with minimal side effects.
Identifiants
pubmed: 34817875
doi: 10.1111/ijd.16008
pmc: PMC9543629
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
911-915Informations de copyright
© 2021 The Authors. International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Med Imaging Radiat Oncol. 2018 Jun;62(3):401-411
pubmed: 29524319
Pract Radiat Oncol. 2020 Jan - Feb;10(1):8-20
pubmed: 31831330
J Am Acad Dermatol. 2016 Feb;74(2):341-7
pubmed: 26589877
J Geriatr Oncol. 2021 Sep;12(7):1110-1113
pubmed: 33736973
JAMA. 2004 May 26;291(20):2441-7
pubmed: 15161894
Int J Mol Sci. 2020 Dec 06;21(23):
pubmed: 33291277
Radiol Med. 2021 Apr;126(4):620-622
pubmed: 33058025
J Gynecol Oncol. 2021 Jul;32(4):e53
pubmed: 34085794
J Dermatol. 2021 Jul;48(7):e288-e311
pubmed: 33963604
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Drugs. 2018 Nov;78(17):1841-1846
pubmed: 30456447
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
World J Gastroenterol. 2013 May 28;19(20):3052-61
pubmed: 23716984
Semin Radiat Oncol. 2008 Oct;18(4):234-9
pubmed: 18725109
Eur Urol Oncol. 2019 Sep;2(5):505-514
pubmed: 31377308
Anticancer Res. 2017 Feb;37(2):825-830
pubmed: 28179337